131I Tositumomab

被引：0
|
作者：
Christine R. Culy
Harriet M. Lamb
机构：
[1] Adis International Limited,
来源：
BioDrugs | 2000年 / 14卷
关键词：
Fludarabine; Objective Response Rate; Autologous Stem Cell Transplant; Unlabelled Antibody; Tositumomab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ 131I tositumomab is a radiolabelled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumour activity as a result of emission of beta particles, and activation of antibody-dependent cellular and complement-mediated cytotoxicity.
引用
收藏
页码：195 / 202
页数：7
相关论文
共 50 条
  • [41] Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
    Leonard, JP
    Coleman, M
    Kostakoglu, L
    Chadburn, A
    Cesarman, E
    Furman, RR
    Schuster, MW
    Niesvizky, R
    Muss, D
    Fiore, J
    Kroll, S
    Tidmarsh, G
    Vallabhajosula, S
    Goldsmith, SJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5696 - 5704
  • [42] 低吸131I率甲亢患者131I治疗疗效评价
    陈辉霖
    梁君
    谢梅
    梁风云
    陈婉茜
    中华核医学杂志, 2003, (04) : 61 - 61
  • [43] 摄131I率低甲亢患者131I治疗疗效探讨
    易战雄
    李卫春
    杜方方
    中国保健营养, 2012, (22) : 5042 - 5042
  • [44] Therapy Response Correlation with Tumor Radio-Sensitivity for Non-Hodgkin's Lymphoma Treated with 131I Tositumomab
    Roberson, P. L.
    Wilderman, S. J.
    Avram, A. M.
    Kaminski, M. S.
    Schipper, M. J.
    Dewaraja, Y. K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S336 - S336
  • [45] Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma
    Jacene, Heather
    Crandall, John
    Kasamon, Yvette L.
    Ambinder, Richard F.
    Piantadosi, Steven
    Serena, Donna
    Kasecamp, Wayne
    Wahl, Richard L.
    MOLECULAR IMAGING AND BIOLOGY, 2017, 19 (03) : 429 - 436
  • [46] Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma
    Heather Jacene
    John Crandall
    Yvette L. Kasamon
    Richard F. Ambinder
    Steven Piantadosi
    Donna Serena
    Wayne Kasecamp
    Richard L. Wahl
    Molecular Imaging and Biology, 2017, 19 : 429 - 436
  • [47] Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Kaminski, MS
    Radford, JA
    Gregory, SA
    Leonard, JP
    Knox, SJ
    Kroll, S
    Wahl, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 7985 - 7993
  • [48] Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab
    Quackenbush, Robert C.
    Horner, Thierry J.
    Williams, Vanessa C.
    Giampietro, Patricia
    Lin, Thomas S.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 779 - 781
  • [49] Cellular Uptake and Computational Analysis of [131I]-Xanthine 131 I]-Xanthine and [131I]-Hypoxanthine 131 I]-Hypoxanthine in Human Prostate Cancer Cell Line (LNCaP)
    Wongso, Hendris
    Mahendra, Isa
    Setiadi, Yanuar
    Rattyananda, Badra Sanditya
    Rizaludin, Asep
    Pranisuari, Ni Made Yuktikamura Galih
    Kusumaningrum, Crhisterra Ellen
    MAKARA JOURNAL OF SCIENCE, 2024, 28 (03)
  • [50] Effect of 131I versus 131I plus antithyroid drug in the management of Graves disease.
    Rong, T
    Ren, KA
    Shi, QW
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 125P - 125P
12345